Katarzyna J Jerzak1,2, Nechama Lipton2, Sharon Nofech-Mozes3, Dina Boles3, Elzbieta Slodkowska3, Gregory R Pond4, Ellen Warner5,6. 1. Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3N5, Canada. 2. Department of Medicine, University of Toronto, Toronto, Canada. 3. Department of Anatomic Pathology, University of Toronto, Toronto, Canada. 4. Department of Oncology, McMaster University, Hamilton, Canada. 5. Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, 2075 Bayview Avenue, Toronto, ON, M4N 3N5, Canada. ellen.warner@sunnybrook.ca. 6. Department of Medicine, University of Toronto, Toronto, Canada. ellen.warner@sunnybrook.ca.
Abstract
PURPOSE: To compare clinical-pathologic characteristics and outcomes of pregnancy-associated, post-partum (PP) and nulliparous (NP) breast cancer (BC) patients and explore mediators of the poor prognosis associated with post-partum BC. METHODS: A prospective database of 233 women ≤ 40 years of age diagnosed with BC between February 2008 and January 2015 was analysed. Clinical-pathologic characteristics and outcomes among pregnant, PP and NP patients were compared using chi-square or Kruskal-Wallis tests. The Kaplan-Meier method was used to estimate disease-free survival (DFS), distant DFS and overall survival (OS). Survival curves were compared using the log-rank test. Univariable Cox proportional hazards regression models were used to evaluate factors that were potentially prognostic for the clinical outcomes of interest; a multivariable Cox model was constructed using a forward stepwise selection process. Androgen receptor (AR), GATA3, PDL1 status and the presence/absence of tumour-infiltrating lymphocytes (TILs) were assessed when possible. Pre-treatment neutrophil and lymphocyte counts were abstracted retrospectively. Statistical significance was defined as a p value ≤ 0.05. RESULTS: Women ≤ 2 years PP had a numerically higher incidence of lymph node-positive and high-grade disease and were significantly more likely to have estrogen receptor-negative BC compared to NP controls. With a median follow-up of 7.2 years, increasingly poor outcomes were observed among NP (longest OS), > 2 years PP, ≤ 2 years PP and pregnant (shortest OS) patients, but these differences were not statistically significant. The ≤ 2 years PP group had significantly lower AR expression, a strong trend toward higher PDL1 expression and a higher expression of stromal TILs compared to NP women. CONCLUSIONS: PPBC patients had numerically lower DFS and OS compared to NP controls. Higher PDL1 and stromal TILs in PPBC suggest that adjuvant immunotherapy may be effective in the post-partum BC subgroup.
PURPOSE: To compare clinical-pathologic characteristics and outcomes of pregnancy-associated, post-partum (PP) and nulliparous (NP) breast cancer (BC) patients and explore mediators of the poor prognosis associated with post-partum BC. METHODS: A prospective database of 233 women ≤ 40 years of age diagnosed with BC between February 2008 and January 2015 was analysed. Clinical-pathologic characteristics and outcomes among pregnant, PP and NP patients were compared using chi-square or Kruskal-Wallis tests. The Kaplan-Meier method was used to estimate disease-free survival (DFS), distant DFS and overall survival (OS). Survival curves were compared using the log-rank test. Univariable Cox proportional hazards regression models were used to evaluate factors that were potentially prognostic for the clinical outcomes of interest; a multivariable Cox model was constructed using a forward stepwise selection process. Androgen receptor (AR), GATA3, PDL1 status and the presence/absence of tumour-infiltrating lymphocytes (TILs) were assessed when possible. Pre-treatment neutrophil and lymphocyte counts were abstracted retrospectively. Statistical significance was defined as a p value ≤ 0.05. RESULTS:Women ≤ 2 years PP had a numerically higher incidence of lymph node-positive and high-grade disease and were significantly more likely to have estrogen receptor-negative BC compared to NP controls. With a median follow-up of 7.2 years, increasingly poor outcomes were observed among NP (longest OS), > 2 years PP, ≤ 2 years PP and pregnant (shortest OS) patients, but these differences were not statistically significant. The ≤ 2 years PP group had significantly lower AR expression, a strong trend toward higher PDL1 expression and a higher expression of stromal TILs compared to NP women. CONCLUSIONS:PPBCpatients had numerically lower DFS and OS compared to NP controls. Higher PDL1 and stromal TILs in PPBC suggest that adjuvant immunotherapy may be effective in the post-partum BC subgroup.
Authors: Hatem A Azim; Luigi Santoro; William Russell-Edu; George Pentheroudakis; Nicholas Pavlidis; Fedro A Peccatori Journal: Cancer Treat Rev Date: 2012-07-09 Impact factor: 12.111
Authors: Frédéric Amant; Gunter von Minckwitz; Sileny N Han; Marijke Bontenbal; Alistair E Ring; Jerzy Giermek; Hans Wildiers; Tanja Fehm; Sabine C Linn; Bettina Schlehe; Patrick Neven; Pieter J Westenend; Volkmar Müller; Kristel Van Calsteren; Brigitte Rack; Valentina Nekljudova; Nadia Harbeck; Michael Untch; Petronella O Witteveen; Kathrin Schwedler; Christoph Thomssen; Ben Van Calster; Sibylle Loibl Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Eryn B Callihan; Dexiang Gao; Sonali Jindal; Traci R Lyons; Elizabeth Manthey; Susan Edgerton; Alexander Urquhart; Pepper Schedin; Virginia F Borges Journal: Breast Cancer Res Treat Date: 2013-02-22 Impact factor: 4.872
Authors: Sungmin Park; Ji Sung Lee; Jae Sun Yoon; Nam Hyoung Kim; Seho Park; Hyun Jo Youn; Jong Won Lee; Jung Eun Lee; Jihyoun Lee; Ho Hur; Joon Jeong; Kweon-Cheon Kim; Soo Youn Bae Journal: Front Oncol Date: 2022-07-01 Impact factor: 5.738